Skip To Main Content
Jozi, an MS patient, using OCREVUS since 2019

About OCREVUS

When it comes to MS treatment, what’s important to you?

If you're starting or switching treatment, there are many things to consider. Learn more about OCREVUS as an option, and talk to your doctor about whether it may be right for you.

*Compared with REBIF® in RMS and placebo in PPMS. REBIF® is a registered trademark of EMD Serono, Inc.
T1 gadolinium-enhancing and T2 hyperintense lesions in RMS and T2 hyperintense lesions in PPMS.
§First dose is split into 2, for a total of 3 treatments the first year.

Why might you choose OCREVUS?

Watch the video above to learn more about OCREVUS and the treatment of RMS and PPMS.

Select Important Safety Information

OCREVUS can cause infusion reactions that can be serious and require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you experience any reactions. Please visit Safety & Side Effects for more information.

Dosing frequency of select relapsing MS treatments

When it comes to a treatment schedule, you have options.

As you and your doctor consider what treatment is right for you, it may help to know how other MS therapies are administered. This is not a complete list of all the possible treatments for MS. The comparison pertains only to differences in dosing and administration and should not be considered a comparison of efficacy or safety. For more information, talk to your healthcare provider.

Dosing frequency chart for multiple sclerosis (MS) treatments

Top 6 FDA-approved RMS treatments for patients starting or switching to a new MS treatment (Feb 2020 to Feb 2021 IQVIA claims and IQVIA NSP), combining both generic and branded formulations.

*Inclusion in top 6 combines branded product plus Glatopa and glatiramer acetate for Copaxone and branded product plus dimethyl fumarate for Tecfidera.
 
This is not a complete list of all the available treatments for RMS. The comparison pertains only to differences in dosing and administration and should not be considered a comparison of efficacy or safety.
 
Trademarks are the property of their respective owners.

Please see each product's respective PI for additional information including indication, dosing, and safety.


How does OCREVUS treat MS?

MS is caused by your immune system attacking the myelin surrounding the nerves in your brain. It is thought that specific types of B cells and T cells in your body are drivers of the attack. B cells play a central role in MS development as they activate the immune system in multiple ways, which includes recruiting T cells to attack neurons.

Until recently, scientists have focused on T cells as a primary target in treating MS. Many scientists now agree that both B cells and T cells play important roles.

OCREVUS works differently.

The exact way OCREVUS works is not fully known. It is believed that OCREVUS works by targeting specific types of B cells. As with any treatment, it's important to talk with your doctor to determine if OCREVUS is right for you.


Proven to be effective in the treatment of RMS and PPMS.

When it comes to MS treatments, what matters most is results. Read more about the safety profile of OCREVUS and what OCREVUS has shown in clinical trials.

Results in Relapsing Multiple Sclerosis (RMS)

See how OCREVUS has been proven to be effective for the treatment of relapsing multiple sclerosis (RMS).

Results in Primary Progressive MS (PPMS)

OCREVUS IS THE ONLY FDA-APPROVED-TREATMENT for primary progressive multiple sclerosis (PPMS).

Important Safety Information

Before starting any new treatment, it's important to review possible side effects and potential risks with your doctor, so together, you can decide if it is right for you.

Alex, an MS patient, using OCREVUS® since 2019

Let’s talk about the infusion experience.

Your first dose will be split between 2 treatments for a total of 3 treatments your first year. Your treatment may be given at an infusion center, your doctor's office, or at home, depending on what you and your doctor decide is right for you.

What is OCREVUS?

OCREVUS is a prescription medicine used to treat:

  • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
  • Primary progressive MS, in adults.

It is not known if OCREVUS is safe and effective in children.

Who should not receive OCREVUS?

Do not receive OCREVUS if you have an active hepatitis B virus (HBV) infection.

Do not receive OCREVUS if you have had a life-threatening allergic reaction to OCREVUS. Tell your healthcare provider if you have had an allergic reaction to OCREVUS or any of its ingredients in the past.

What is the most important information I should know about OCREVUS?

OCREVUS can cause serious side effects, including:

  • Infusion reactions: Infusion reactions are a common side effect of OCREVUS, which can be serious and may require you to be hospitalized. You will be monitored during your infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Tell your healthcare provider or nurse if you get any of these symptoms:
    • itchy skin
    • rash
    • hives
    • tiredness
    • coughing or wheezing
    • trouble breathing
    • throat irritation or pain
    • feeling faint
    • fever
    • redness on your face (flushing)
    • nausea
    • headache
    • swelling of the throat
    • dizziness
    • shortness of breath
    • fatigue
    • fast heart beat

These infusion reactions can happen for up to 24 hours after your infusion. It is important that you call your healthcare provider right away if you get any of the signs or symptoms listed above after each infusion. If you get infusion reactions, your healthcare provider may need to stop or slow down the rate of your infusion.

  • Infection:
    • OCREVUS increases your risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Infections are a common side effect, which can be serious. Tell your healthcare provider if you have an infection or have any of the following signs of infection including fever, chills, or a cough that does not go away. Signs of herpes include cold sores, shingles, genital sores, skin rash, pain, and itching. Signs of more serious herpes infection include: changes in vision, eye redness or eye pain, severe or persistent headache, stiff neck, and confusion. Signs of infection can happen during treatment or after you have received your last dose of OCREVUS. Tell your healthcare provider right away if you have an infection. Your healthcare provider should delay your treatment with OCREVUS until your infection is gone.
    • Hepatitis B virus (HBV) reactivation: Before starting treatment with OCREVUS, your healthcare provider will do blood tests to check for hepatitis B viral infection. If you have ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. Your healthcare provider will monitor you if you are at risk for hepatitis B virus reactivation during treatment and after you stop receiving OCREVUS.
    • Weakened immune system: OCREVUS taken before or after other medicines that weaken the immune system could increase your risk of getting infections.
  • Progressive Multifocal Leukoencephalopathy (PML): PML is a rare brain infection that usually leads to death or severe disability, and has been reported with OCREVUS. Symptoms of PML get worse over days to weeks. It is important that you call your healthcare provider right away if you have any new or worsening neurologic signs or symptoms that have lasted several days, including problems with:
    • thinking        
    • eyesight
    • strength
    • balance
    • weakness on 1 side of your body
    • using your arms or legs
  • Decreased immunoglobulins: OCREVUS may cause a decrease in some types of immunoglobulins. Your healthcare provider will do blood tests to check your blood immunoglobulin levels.

Before receiving OCREVUS, tell your healthcare provider about all of your medical conditions, including if you:

  • have ever taken, take, or plan to take medicines that affect your immune system, or other treatments for MS.
  • have ever had hepatitis B or are a carrier of the hepatitis B virus.
  • have a history of inflammatory bowel disease or colitis.
  • have had a recent vaccination or are scheduled to receive any vaccinations. 
    • You should receive any required ‘live’ or ‘live-attenuated’ vaccines at least 4 weeks before you start treatment with OCREVUS. You should not receive ‘live’ or ‘live attenuated’ vaccines while you are being treated with OCREVUS and until your healthcare provider tells you that your immune system is no longer weakened.
    • When possible, you should receive any ‘non-live’ vaccines at least 2 weeks before you start treatment with OCREVUS. If you would like to receive any non-live (inactivated) vaccines, including the seasonal flu vaccine, while you are being treated with OCREVUS, talk to your healthcare provider.
    • If you have a baby and you received OCREVUS during your pregnancy, it is important to tell your baby’s healthcare provider about receiving OCREVUS so they can decide when your baby should be vaccinated.
  • are pregnant, think that you might be pregnant, or plan to become pregnant. It is not known if OCREVUS will harm your unborn baby. You should use birth control (contraception) during treatment with OCREVUS and for 6 months after your last infusion of OCREVUS. Talk with your healthcare provider about what birth control method is right for you during this time.
    • Pregnancy Registry. There is a pregnancy registry for women who take OCREVUS during pregnancy. If you become pregnant while receiving OCREVUS, tell your healthcare provider right away. Talk to your healthcare provider about registering with the OCREVUS Pregnancy Registry. The purpose of this registry is to collect information about your health and your baby’s health. Your healthcare provider can enroll you in this registry by calling 1-833-872-4370 or visiting www.ocrevuspregnancyregistry.com.
  • are breastfeeding or plan to breastfeed. It is not known if OCREVUS passes into your breast milk. Talk to your healthcare provider about the best way to feed your baby if you take OCREVUS.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of OCREVUS?

OCREVUS may cause serious side effects, including:

  • Risk of cancers (malignancies) including breast cancer. Follow your healthcare provider’s instructions about standard screening guidelines for breast cancer.
  • Inflammation of the colon, or colitis: Tell your healthcare provider if you have any symptoms of colitis, such as:
    • Diarrhea (loose stools) or more frequent bowel movements than usual
    • Stools that are black, tarry, sticky or have blood or mucus
    • Severe stomach-area (abdomen) pain or tenderness

These are not all the possible side effects of OCREVUS.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Genentech at (888) 835-2555.

For more information, go to www.OCREVUS.com or call 1-844-627-3887.

Please see additional Important Safety Information throughout and click here for full Prescribing Information and Medication Guide.

    • OCREVUS Prescribing Information. Genentech, Inc. 2016.

      OCREVUS Prescribing Information. Genentech, Inc. 2016.